TY - CONF
T1 - Potential of improving the treatment of tuberculosis through nanomedicine
AU - Semete, Boitumelo
AU - Kalombo, Lonji
AU - Katata, Lebogang
AU - Chelule, Paul
AU - Booysen, Laetitia
AU - Lemmer, Yolandy
AU - Naidoo, Saloshnee
AU - Ramalapa, Bathabile
AU - Hayeshi, Rose
AU - Swai, Hulda S.
PY - 2012/6/1
Y1 - 2012/6/1
N2 - Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200-300 nm were synthesized, with a drug encapsulation efficiency of 50-65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment. © Taylor & Francis Group, LLC.
AB - Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200-300 nm were synthesized, with a drug encapsulation efficiency of 50-65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment. © Taylor & Francis Group, LLC.
UR - https://www.scopus.com/pages/publications/84861548021
UR - https://www.scopus.com/pages/publications/84861548021#tab=citedBy
U2 - 10.1080/15421406.2012.635531
DO - 10.1080/15421406.2012.635531
M3 - Paper
SP - 317
EP - 330
T2 - Molecular Crystals and Liquid Crystals
Y2 - 1 June 2012
ER -
